NASDAQ: CYTHCyclo Therapeutics Inc Stock
$0.65+0.01 (+1.56%)
Updated Sep 13, 2024
CYTH Price
$0.65
Fair Value Price
N/A
Market Cap
$18.57M
52 Week Low
$0.60
52 Week High
$2.12
P/E
-0.74x
P/B
-3.62x
P/S
32.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.13M
Earnings
-$20.74M
Gross Margin
93%
Operating Margin
-1,831.29%
Profit Margin
-1,831.3%
Debt to Equity
-1.92
Operating Cash Flow
-$18M
Beta
0.94
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CYTH Overview
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company developing cyclodextrin-based products for the treatment of various diseases. It also sells cyclodextrins and related products to pharmaceutical and nutritional companies for use in diagnostics and specialty drugs. Known as CTD Holdings, Inc. until 2019, Cyclo Therapeutics was incorporated in 1990 and is based in Gainesville, FL.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYTH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CYTH is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CYTH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CYTH due diligence checks available for Premium users.
Be the first to know about important CYTH news, forecast changes, insider trades & much more!
CYTH News
Valuation
CYTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.74x
Industry
20.24x
Market
23.21x
CYTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.62x
Industry
2.31x
CYTH's financial health
Profit margin
Revenue
$123.1k
Net Income
-$6.0M
Profit Margin
-4,858.7%
CYTH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CYTH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.7M
Liabilities
$9.8M
Debt to equity
-1.92
CYTH's short-term liabilities ($9.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYTH's short-term assets ($4.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
$0.0
Financing
$2.0M
CYTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYTH vs Pharmaceutical Stocks
Cyclo Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.